EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

Peter Ashcroft iD, Sarah McFann iD, Alex Ferguson iD, Arthur Van De Vyver iD, Suzanne Gaudet iD, Eshita Khera iD, Jan-Frederik Schlender iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70077 ↗

At a glance

Übersichtsarbeit in Clinical Pharmacology & Therapeutics, 2026. Written by Peter Ashcroft and 6 co-authors. Institution: Biomedical Research, Novartis, Basel, Switzerland. Major MEDLINE topics: Hematologic Neoplasms, Immunotherapy, Adoptive, T-Lymphocytes, Translational Research, Biomedical. 100 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders. This review discusses the foundational principles for mechanistic modeling to provide a unified assessment framework for cross‐modality (i.e., CAR‐T cells vs. TCEs) and cross‐indication (i.e., oncology vs. immunology) translation. This framework captures the unique elements of each modality, such as CAR‐T cellular kinetics, TCE pharmacokinetics, and complex formation with target cells, as well as shared elements such as B‐cell kinetics and biodistribution across indications. We describe how this integrated approach can lead to informed decision making for more personalized and effective treatment strategies with these immune therapies.

Subjects

MeSH terms (MEDLINE)

Hematologic NeoplasmsImmunotherapy, AdoptiveT-LymphocytesTranslational Research, BiomedicalHumansPrecision MedicineReceptors, Chimeric AntigenAnimals

Substances

Receptors, Chimeric Antigen

Authors and institutions

  • Biomedical Research, Novartis, Basel, Switzerland.
  • Biomedical Research, Novartis, Cambridge, Massachusetts, USA.

ORCID profiles: Peter Ashcroft, Sarah McFann, Alex Ferguson, Arthur Van De Vyver, Suzanne Gaudet, Eshita Khera, Jan-Frederik Schlender

Cite

APA

Ashcroft, P., McFann, S., Ferguson, A., Van De Vyver, A., Gaudet, S., Khera, E., & Schlender, J. F. (2026). Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70077

Vancouver

Ashcroft P, McFann S, Ferguson A, Van De Vyver A, Gaudet S, Khera E, et al. Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70077

BibTeX
@article{Ashcroft2026,
  author = {Ashcroft, Peter and McFann, Sarah and Ferguson, Alex and Van De Vyver, Arthur and Gaudet, Suzanne and Khera, Eshita and Schlender, Jan-Frederik},
  title = {Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70077}
}
Start for free →